Editors

Impact

Original Research

16 July 2024

Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non–small cell lung cancer: a retrospective controlled real-world study

Weipeng Shao

, 5 more and

Hongbo Guo

1,263 views

0 citations

Original Research

04 July 2024

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis

Xueming Xia

, 4 more and

Yongmei Liu

803 views

0 citations

Case Report

21 June 2024

EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review

Hong Lin

, 4 more and

Yingcheng Lin

654 views

0 citations

Case Report

06 June 2024

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance

Wanming He

, 4 more and

Wubing Tang

801 views

0 citations

Case Report

11 March 2024

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports

Loc Carlo Bao

, 5 more and

Stefano Indraccolo

1,406 views

0 citations

Original Research

22 February 2024

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

Ningning Yan

, 3 more and

Xingya Li

1,248 views

0 citations

Original Research

03 October 2023

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

Ping-Chih Hsu

, 10 more and

Cheng-Ta Yang

1,218 views

1 citations

Review

15 August 2023

Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects

Daoan Cheng

, 6 more and

Mei Ji

4,254 views

8 citations

Original Research

08 November 2022

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Wei Dong

, 4 more and

Shanliang Hu

1,367 views

3 citations

Case Report

25 July 2022

Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report

Pascal Wang

, 5 more and

Boris Duchemann

3,307 views

3 citations

Systematic Review

07 June 2022

Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis

Xiao-Fang Yi

, 7 more and

Cheng-Bo Han

2,140 views

6 citations

Case Report

Frontiers in Oncology

Long-term Remission of Malignant Pleural and Peritoneal Effusion in a Case of Advanced Lung Adenocarcinoma Treated with Combined Crizotinib and Anlotinib Therapy

Jin Tian

, 5 more and

Jun Xiao

1,427 views

1 citations

Original Research

Frontiers in Oncology

Characterizing the secretome of EGFR mutant lung adenocarcinoma

Jennifer K. Luu

, 9 more and

William W. Lockwood

1,584 views

1 citations

Systematic Review

Frontiers in Pharmacology

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Haosheng Zheng

, 6 more and

Hongying Liao

1,312 views

0 citations

Opinion

Frontiers in Oncology

The great need to overcome osimertinib resistance in advanced nonsmall cell lung cancer: from combination strategies to fourthgeneration tyrosine kinase inhibitors

Giuseppe Bronte

, 2 more and

Lucio Crinò

2,198 views

2 citations

Case Report

Frontiers in Immunology

Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, EGFR mutation and high microsatellite instability

Meiling Yang

, 2 more and

Jingmin Deng

1,684 views

2 citations

Original Research

Frontiers in Oncology

Treatment decision for recurrences in non-small cell lung cancer (NSCLC) during or after adjuvant osimertinib: an international Delphi consensus report

Myriam Mirza

, 13 more and

Yi-Long Wu

2,408 views

0 citations

Original Research

Frontiers in Oncology

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer

Song Hu

, 4 more and

Chong Li

1,044 views

0 citations

Case Report

Frontiers in Oncology

Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case series

Petros Christopoulos

, 7 more and

Eckart Laack

1,439 views

0 citations

Original Research

Frontiers in Oncology

Weighted gene co-expression network analysis and whole genome sequencing identify potential lung cancer biomarkers

Mireguli Abudereheman

, 1 more and

Baidurula Ainitu

912 views

0 citations

Fetching...

Home Frontiers in Oncology…Thoracic Oncology…Research Topics

Enjoyed this Research Topic?

Share it using

Advances in the use of EGFR TKIs in the Treatment of NSCLC

34.8K

views

145

authors

articles